Data from a trial presented at the annual EuroPCR conference showed the use of Boston Scientific's Lotus heart valve in high-risk aortic stenosis patients led to a lower combined rate of mortality, valvular leakage and disabling stroke after one year, compared with Medtronic's CoreValve device. However, more Lotus device patients required a permanent pacemaker within 30 days of implantation.
Data show positive results for Boston Scientific's Lotus heart valve
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.